Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Frequent downregulation of miR-34 family in human ovarian cancers.

Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY.

Clin Cancer Res. 2010 Feb 15;16(4):1119-28. doi: 10.1158/1078-0432.CCR-09-2642. Epub 2010 Feb 9.

2.

MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.

Tang W, Jiang Y, Mu X, Xu L, Cheng W, Wang X.

Cell Signal. 2014 Jul;26(7):1420-6. doi: 10.1016/j.cellsig.2014.03.002. Epub 2014 Mar 6.

PMID:
24607788
3.
4.

MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met.

Wang LG, Ni Y, Su BH, Mu XR, Shen HC, Du JJ.

Int J Oncol. 2013 Mar;42(3):957-62. doi: 10.3892/ijo.2013.1767. Epub 2013 Jan 10.

PMID:
23314612
5.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.

Meng X, Joosse SA, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H.

Br J Cancer. 2015 Nov 3;113(9):1358-66. doi: 10.1038/bjc.2015.340. Epub 2015 Sep 22.

PMID:
26393886
6.

miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.

Xia B, Yang S, Liu T, Lou G.

Mol Cancer. 2015 Mar 11;14:57. doi: 10.1186/s12943-015-0322-4.

7.

MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.

Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, Di W, Qiu L.

PLoS One. 2014 May 9;9(5):e96718. doi: 10.1371/journal.pone.0096718. eCollection 2014.

8.

Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.

Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, Asano H, Tsukuda K, Aoe K, Miyoshi S.

Lung Cancer. 2012 Apr;76(1):32-8. doi: 10.1016/j.lungcan.2011.10.002. Epub 2011 Nov 1.

PMID:
22047961
9.

Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.

Peng DX, Luo M, Qiu LW, He YL, Wang XF.

Oncol Rep. 2012 Apr;27(4):1238-44. doi: 10.3892/or.2012.1625. Epub 2012 Jan 11.

10.

Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.

Javeri A, Ghaffarpour M, Taha MF, Houshmand M.

Med Oncol. 2013 Mar;30(1):413. doi: 10.1007/s12032-012-0413-7. Epub 2013 Jan 6.

PMID:
23292869
11.

Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer.

Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, Hermeking H.

Clin Cancer Res. 2013 Feb 1;19(3):710-20. doi: 10.1158/1078-0432.CCR-12-1703. Epub 2012 Dec 14.

12.

Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.

Vogt M, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A, Hermeking H.

Virchows Arch. 2011 Mar;458(3):313-22. doi: 10.1007/s00428-010-1030-5. Epub 2011 Jan 12.

PMID:
21225432
13.

MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer.

Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew KP, Wu YL, Zhang S.

Oncotarget. 2014 Dec 15;5(23):12291-303.

14.

miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells.

Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X.

Cancer Lett. 2009 Mar 8;275(1):44-53. doi: 10.1016/j.canlet.2008.09.035. Epub 2008 Nov 8.

PMID:
19006648
15.

MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).

Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, Batchu RB.

Pharm Res. 2011 Dec;28(12):3079-90. doi: 10.1007/s11095-011-0547-x. Epub 2011 Aug 5.

PMID:
21818714
16.

miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met.

Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ, Mao SS, Zhang GH, Xu XC, Zhang N.

Cancer. 2011 Jul 1;117(13):2842-52. doi: 10.1002/cncr.25860. Epub 2011 Jan 10.

17.

[Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].

Zhang Q, He XJ, Ma LP, Li N, Yang J, Cheng YX, Cui H.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):885-90. Chinese.

PMID:
22340095
18.

MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.

Zhang Y, Schiff D, Park D, Abounader R.

PLoS One. 2014 Mar 12;9(3):e91546. doi: 10.1371/journal.pone.0091546. eCollection 2014.

19.

Expression and prognostic significance of microRNA-451 in human epithelial ovarian cancer.

Ling S, Ruiqin M, Guohong Z, Ying W.

Eur J Gynaecol Oncol. 2015;36(4):463-8.

PMID:
26390704
20.

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Körner S, Wang W, Boccaccio C, Thorgeirsson SS, Comoglio PM, Hermeking H, Nikitin AY.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14240-5. doi: 10.1073/pnas.1017536108. Epub 2011 Aug 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk